BR9607582A - Composto e peptídeo ou substância peptidomimética - Google Patents

Composto e peptídeo ou substância peptidomimética

Info

Publication number
BR9607582A
BR9607582A BR9607582A BR9607582A BR9607582A BR 9607582 A BR9607582 A BR 9607582A BR 9607582 A BR9607582 A BR 9607582A BR 9607582 A BR9607582 A BR 9607582A BR 9607582 A BR9607582 A BR 9607582A
Authority
BR
Brazil
Prior art keywords
peptide
compound
peptidomimetic
substance
peptidomimetic substance
Prior art date
Application number
BR9607582A
Other languages
English (en)
Inventor
Hans Wolfgang Hoffken
Wilfried Hornberger
Hans-Joachim Bohm
Stefan Koser
Thomas Zierke
Helmut Mack
Thomas Pfeiffer
Werner Seitz
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of BR9607582A publication Critical patent/BR9607582A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06139Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
BR9607582A 1995-02-17 1996-02-12 Composto e peptídeo ou substância peptidomimética BR9607582A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19505484 1995-02-17
DE19506611 1995-02-24
DE19507455 1995-03-03
PCT/EP1996/000582 WO1996025426A1 (de) 1995-02-17 1996-02-12 Neue dipeptidische amidine als thrombin-inhibitoren

Publications (1)

Publication Number Publication Date
BR9607582A true BR9607582A (pt) 1998-07-07

Family

ID=27214848

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9607582A BR9607582A (pt) 1995-02-17 1996-02-12 Composto e peptídeo ou substância peptidomimética

Country Status (26)

Country Link
US (3) US6030972A (pt)
EP (1) EP0873356A1 (pt)
JP (1) JPH11500120A (pt)
KR (1) KR100388185B1 (pt)
CN (1) CN1198839C (pt)
AR (1) AR002277A1 (pt)
AU (1) AU708001B2 (pt)
BG (1) BG63697B1 (pt)
BR (1) BR9607582A (pt)
CA (1) CA2211109A1 (pt)
CZ (1) CZ245797A3 (pt)
EA (1) EA199700186A1 (pt)
FI (1) FI973360A0 (pt)
HR (1) HRP960075B1 (pt)
HU (1) HUP9800263A3 (pt)
IL (1) IL117165A0 (pt)
MX (1) MX9706069A (pt)
MY (1) MY132115A (pt)
NO (1) NO973764L (pt)
NZ (1) NZ302649A (pt)
PL (1) PL321759A1 (pt)
SI (1) SI9620037A (pt)
SK (1) SK104697A3 (pt)
TR (1) TR199700803T1 (pt)
TW (1) TW450968B (pt)
WO (1) WO1996025426A1 (pt)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5705487A (en) * 1994-03-04 1998-01-06 Eli Lilly And Company Antithrombotic agents
US5707966A (en) * 1994-03-04 1998-01-13 Eli Lilly And Company Antithrombotic agents
US5726159A (en) * 1994-03-04 1998-03-10 Eli Lilly And Company Antithrombotic agents
MX9706069A (es) * 1995-02-17 1997-10-31 Basf Ag Nuevos inhibidores de la trombina.
US5914319A (en) * 1995-02-27 1999-06-22 Eli Lilly And Company Antithrombotic agents
US5710130A (en) * 1995-02-27 1998-01-20 Eli Lilly And Company Antithrombotic agents
SA96170106A (ar) 1995-07-06 2005-12-03 أسترا أكتيبولاج مشتقات حامض أميني جديدة
TWI238827B (en) * 1995-12-21 2005-09-01 Astrazeneca Ab Prodrugs of thrombin inhibitors
SE9602263D0 (sv) 1996-06-07 1996-06-07 Astra Ab New amino acid derivatives
AU3496297A (en) * 1996-06-25 1998-01-14 Eli Lilly And Company Anticoagulant agents
EP1110968B1 (en) * 1996-06-25 2003-10-01 Eli Lilly & Company Intermediate for the preparation of Thrombininhibitors as anticoagulant agents
US6200967B1 (en) 1996-06-25 2001-03-13 Eli Lilly And Company Anticoagulant agents
SE9602646D0 (sv) 1996-07-04 1996-07-04 Astra Ab Pharmaceutically-useful compounds
DE19632772A1 (de) * 1996-08-14 1998-02-19 Basf Ag Neue Benzamidine
DE19632773A1 (de) * 1996-08-14 1998-02-19 Basf Ag Neue Thrombininhibitoren
AR013084A1 (es) 1997-06-19 2000-12-13 Astrazeneca Ab Derivados de amidino utiles como inhibidores de la trombina, composicion farmaceutica, utilizacion de dichos compuestos para la preparacion demedicamentos y proceso para la preparacion de los compuestos mencionados
SE9704543D0 (sv) 1997-12-05 1997-12-05 Astra Ab New compounds
EP1049673A1 (de) * 1998-01-26 2000-11-08 Basf Aktiengesellschaft Heterocyclische amidine als kallikrein protease inhibitoren
NZ508005A (en) 1998-04-24 2003-05-30 Dimensional Pharm Inc Amino acid amidinohydrazones, alkoxyguanidines and aminoguanidines useful as serine protease inhibitors
SE9804313D0 (sv) * 1998-12-14 1998-12-14 Astra Ab New compounds
US6486193B2 (en) 1998-12-31 2002-11-26 Aventis Pharmaceuticals Inc. 3-substituted pyrrolidines useful as inhibitors of matrix metalloproteinases
NZ512714A (en) 1999-01-13 2003-10-31 Astrazeneca Ab Amidinobenzylamine derivatives useful as thrombin inhibitors
EP1169338B1 (de) 1999-04-09 2004-11-03 Abbott GmbH & Co. KG Niedermolekulare inhibitoren von komplementproteasen
HUP0202431A3 (en) * 1999-04-09 2003-03-28 Basf Ag Prodrugs of thrombin inhibitors
AR023510A1 (es) 1999-04-21 2002-09-04 Astrazeneca Ab Un equipo de partes, formulacion farmaceutica y uso de un inhibidor de trombina.
DE19921346A1 (de) 1999-05-10 2000-11-16 Basf Ag Sprühtrocknung von Thrombininhibitoren
DE50008187D1 (de) 1999-05-10 2004-11-18 Abbott Gmbh & Co Kg Salze von Thrombininhibitoren
SE0001803D0 (sv) 2000-05-16 2000-05-16 Astrazeneca Ab New compounds i
DE10029015A1 (de) 2000-06-15 2001-12-20 Curacyte Ag Hemmstoffe für den Gerinnungsfaktor Xa
US6433186B1 (en) 2000-08-16 2002-08-13 Astrazeneca Ab Amidino derivatives and their use as thormbin inhibitors
DE10049937A1 (de) * 2000-10-06 2002-04-11 Knoll Ag Niedermolekulare Inhibitoren von Serinproteasen mit Polyhydroxyalkyl- und Polyhydroxycycloalkylresten
AR035216A1 (es) 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
US7129233B2 (en) 2000-12-01 2006-10-31 Astrazeneca Ab Mandelic acid derivatives and their use as thrombin inhibitors
DE10064797A1 (de) * 2000-12-22 2002-06-27 Knoll Ag Orale und parenterale pharmazeutische Formulierung, umfassend eine niedermolekulare Thrombininhibitor-Pro-Pharmakon
US6774110B2 (en) * 2001-03-19 2004-08-10 Lg Life Sciences Ltd. Orally available peptidic thrombin inhibitors
AR034517A1 (es) * 2001-06-21 2004-02-25 Astrazeneca Ab Formulacion farmaceutica
AU2003219039A1 (en) * 2002-03-11 2003-09-22 Curacyte Ag Urokinase inhibitors, production and use thereof
DE10210590A1 (de) * 2002-03-11 2003-10-02 Curacyte Ag Hemmstoffe des Gerinnungsfaktors Xa, ihre Herstellung und Verwendung
CA2481313A1 (en) 2002-04-12 2003-10-23 Merck & Co., Inc. Bicyclic amides
SE0201659D0 (sv) * 2002-05-31 2002-05-31 Astrazeneca Ab Modified release pharmaceutical formulation
SE0201661D0 (sv) * 2002-05-31 2002-05-31 Astrazeneca Ab New salts
DE10301300B4 (de) 2003-01-15 2009-07-16 Curacyte Chemistry Gmbh Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein
US7781424B2 (en) * 2003-05-27 2010-08-24 Astrazeneca Ab Modified release pharmaceutical formulation
DE10342108A1 (de) * 2003-09-11 2005-04-14 Curacyte Chemistry Gmbh Basisch-substituierte Benzylaminanaloga als Inhibitoren des Gerinnungsfaktors Xa, ihre Herstellung und Verwendung
JP2007510651A (ja) * 2003-11-04 2007-04-26 メルク エンド カムパニー インコーポレーテッド 糖尿病の治療又は予防のためのジペプチジルペプチダーゼ−iv阻害剤としての縮合フェニルアラニン誘導体
US7795205B2 (en) 2004-04-12 2010-09-14 Canyon Pharmaceuticals, Inc. Methods for effecting regression of tumor mass and size in a metastasized pancreatic tumor
WO2005111003A1 (en) 2004-04-29 2005-11-24 Abbott Laboratories Amino-tetrazoles analogues and methods of use
JP4561197B2 (ja) * 2004-06-28 2010-10-13 宇部興産株式会社 5−(4−テトラヒドロピラニル)ヒダントインの製法及びその中間体
JP4572618B2 (ja) * 2004-08-04 2010-11-04 宇部興産株式会社 4−テトラヒドロピラニルグリシンの製法
US7524354B2 (en) * 2005-07-07 2009-04-28 Research Foundation Of State University Of New York Controlled synthesis of highly monodispersed gold nanoparticles
DE102006050672A1 (de) 2006-10-24 2008-04-30 Curacyte Discovery Gmbh Hemmstoffe des Plasmins und des Plasmakallikreins
TW200827336A (en) 2006-12-06 2008-07-01 Astrazeneca Ab New crystalline forms
US20090061000A1 (en) * 2007-08-31 2009-03-05 Astrazeneca Ab Pharmaceutical formulation use 030
CN102464701B (zh) * 2010-11-08 2015-10-21 上海医药工业研究院 一类新型化合物、其制备方法及用途
TWI773657B (zh) 2015-12-18 2022-08-11 美商亞德利克斯公司 作爲非全身tgr5促效劑之經取代之4-苯基吡啶化合物

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2113982A1 (de) * 1970-03-25 1971-10-14 Sumitomo Chemical Co Verfahren zur Herstellung von Benzodiazepinen
DE2059922A1 (de) * 1970-12-05 1972-06-15 Boehringer Mannheim Gmbh Neue N(6)-Aralkyl-adenosin-Derivate und Verfahren zur Herstellung derselben
HU178398B (en) * 1979-06-12 1982-04-28 Gyogyszerkutato Intezet Process for producing new agmatine derivatives of activity against haemagglutination
GB8305985D0 (en) * 1983-03-04 1983-04-07 Szelke M Enzyme inhibition
HU192646B (en) * 1984-12-21 1987-06-29 Gyogyszerkutato Intezet Process for preparing new n-alkyl-peptide aldehydes
ZA86746B (en) * 1985-02-04 1986-09-24 Merrell Dow Pharma Novel peptidase inhibitors
US5187157A (en) * 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
EP0362002B1 (en) * 1988-09-01 1995-07-26 Merrell Dow Pharmaceuticals Inc. HIV protease inhibitors
ZA897515B (en) * 1988-10-07 1990-06-27 Merrell Dow Pharma Novel peptidase inhibitors
CA2021660A1 (en) * 1989-07-26 1991-01-27 Philippe Bey Peptidase inhibitors
GB9017694D0 (en) * 1990-08-13 1990-09-26 Sandoz Ltd Improvements in or relating to organic chemistry
GB9024129D0 (en) * 1990-11-06 1990-12-19 Thrombosis Research Trust Inhibitors and substrates of thrombin
EP0503203A1 (en) * 1991-03-15 1992-09-16 Merrell Dow Pharmaceuticals Inc. Novel thrombin inhibitors
CA2075154A1 (en) * 1991-08-06 1993-02-07 Neelakantan Balasubramanian Peptide aldehydes as antithrombotic agents
SE9102462D0 (sv) * 1991-08-28 1991-08-28 Astra Ab New isosteric peptides
ZA928581B (en) * 1991-11-12 1994-05-06 Lilly Co Eli Antithrombotic agents
SE9103612D0 (sv) * 1991-12-04 1991-12-04 Astra Ab New peptide derivatives
CA2129339C (en) * 1992-02-14 2002-09-10 George P. Vlasuk Inhibitors of thrombosis
AU663169B2 (en) * 1992-03-04 1995-09-28 Gyogyszerkutato Intezet Kft New anticoagulant peptide derivatives and pharmaceutical compositions containing the same as well as a process for the preparation thereof
FR2695562B1 (fr) * 1992-09-11 1994-10-14 Synthelabo Utilisation d'un inhibiteur direct de la thrombine pour la fabrication d'un médicament à activité thrombolytique.
US5371072A (en) * 1992-10-16 1994-12-06 Corvas International, Inc. Asp-Pro-Arg α-keto-amide enzyme inhibitors
US5346129A (en) * 1993-05-17 1994-09-13 Honeywell Inc. Indoor climate controller system adjusting both dry-bulb temperature and wet-bulb or dew point temperature in the enclosure
US5783563A (en) * 1993-06-03 1998-07-21 Astra Aktiebolag Method for treatment or prophylaxis of venous thrombosis
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
CA2140598C (en) * 1994-01-27 2010-03-09 Masahiro Ohshima Prolineamide derivatives
US5707966A (en) * 1994-03-04 1998-01-13 Eli Lilly And Company Antithrombotic agents
IL112795A (en) * 1994-03-04 2001-01-28 Astrazeneca Ab Derivatives of peptides as antithrombotic drugs, their preparation, and pharmaceutical preparations containing them
US5726159A (en) * 1994-03-04 1998-03-10 Eli Lilly And Company Antithrombotic agents
US5705487A (en) * 1994-03-04 1998-01-06 Eli Lilly And Company Antithrombotic agents
CN1181091C (zh) 1994-04-26 2004-12-22 西莱克泰德公司 因子Xa抑制剂
US5849510A (en) * 1994-04-26 1998-12-15 Selectide Corporation Factor Xa inhibitors
US5543396A (en) * 1994-04-28 1996-08-06 Georgia Tech Research Corp. Proline phosphonate derivatives
DE4421052A1 (de) * 1994-06-17 1995-12-21 Basf Ag Neue Thrombininhibitoren, ihre Herstellung und Verwendung
MX9706069A (es) * 1995-02-17 1997-10-31 Basf Ag Nuevos inhibidores de la trombina.
US5710130A (en) * 1995-02-27 1998-01-20 Eli Lilly And Company Antithrombotic agents

Also Published As

Publication number Publication date
AU4875196A (en) 1996-09-04
JPH11500120A (ja) 1999-01-06
NO973764D0 (no) 1997-08-15
SI9620037A (sl) 1998-02-28
MX9706069A (es) 1997-10-31
CA2211109A1 (en) 1996-08-22
EA199700186A1 (ru) 1998-02-26
FI973360A (fi) 1997-08-15
MY132115A (en) 2007-09-28
KR100388185B1 (ko) 2003-11-28
HRP960075A2 (en) 1997-12-31
CZ245797A3 (cs) 1998-06-17
AU708001B2 (en) 1999-07-29
IL117165A0 (en) 1996-06-18
KR19980702285A (ko) 1998-07-15
BG63697B1 (bg) 2002-09-30
HUP9800263A2 (hu) 1998-06-29
AR002277A1 (es) 1998-03-11
PL321759A1 (en) 1997-12-22
HRP960075B1 (en) 2004-10-31
TR199700803T1 (xx) 1998-02-21
CN1175953A (zh) 1998-03-11
US20020169318A1 (en) 2002-11-14
SK104697A3 (en) 1998-11-04
HUP9800263A3 (en) 1998-07-28
US6444817B1 (en) 2002-09-03
FI973360A0 (fi) 1997-08-15
CN1198839C (zh) 2005-04-27
US6900319B2 (en) 2005-05-31
TW450968B (en) 2001-08-21
NZ302649A (en) 2000-01-28
NO973764L (no) 1997-10-15
EP0873356A1 (de) 1998-10-28
WO1996025426A1 (de) 1996-08-22
US6030972A (en) 2000-02-29
BG101835A (en) 1998-05-29

Similar Documents

Publication Publication Date Title
BR9607582A (pt) Composto e peptídeo ou substância peptidomimética
BR9607317A (pt) Peptídios e composição farmacêutica
BR9607318A (pt) Peptidos e composição farmacêutica
BR9504791B1 (pt) composto de polipeptìdeo e composição farmacêutica.
IS4496A (is) Úðablöndur úr peptíðum og próteinum
BR9500784A (pt) Composto e formulação farmacêutica
BR9504060A (pt) Composto e formulação farmacêutica
DE69625368T2 (de) Schweisshemmende deodorierende präparaten
IS4664A (is) Ný peptíð-ópíóíð
NO973287D0 (no) Innåndingsbar væske - eliminasjonsanalyse
BR9607851B1 (pt) combinaÇço e formulaÇço farmacÊutica.
PT871656E (pt) Derivados de dolastatina sua preparacao e utilizacao
BR9606984A (pt) Vassoura e conjunto de vassoura
ID24669A (id) Turunan-turunan dolastatin 15
NO985680D0 (no) Peptidderivater
FR2745004B1 (fr) Peptide antibacterien et antifongique
BR9610109A (pt) Fecho e uso mesmo
NO983849D0 (no) Peptidderivater
ID19147A (id) Ksilanase dan pemakaiannya
FI963334A (fi) Tyrosinaasista peräisin olevat eristetyt peptidit ja niiden käyttö
DK0826679T3 (da) Naphthylforbindelser og -præparater
BR9606951A (pt) Proteinas matantes
BR9606756A (pt) Peptídeo
IT1294006B1 (it) Soffitto e procedimento per la sua costruzione
NO981052D0 (no) Peptidderivater

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 3A , 4A , 5A E 6A , 8A , 9A , 10A , 11A , 12A , 13A E 14A ANUI DADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2060 DE 29/06/2010.